Overview

Colchicine in ST-elevation Myocardial Infarction

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
- There is evidence that inflammatory processes may play detrimental role during the acute phase of myocardial infarction - The hypothesis of this study is that colchicine, by its anti-inflammatory action, may lead to reduction in infarct size, when administered during the acute phase of myocardial infarction
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
G.Gennimatas General Hospital
Treatments:
Colchicine
Criteria
Inclusion Criteria:

The study will enroll patients 18 years old or older who present to the hospital within
twelve (12) hours of the onset of chest pain and who had ST segment elevation >1 mm in two
contiguous limb leads or ST segment elevation >2 mm in two consecutive precordial leads or
new onset of left bundle branch block (LBBB) in a twelve lead electrocardiogram and for
whom the decision was made to be taken to the cath lab to perform angioplasty of the
coronary vessels.

Excluded patients:

- > 80 years old

- with active inflammatory diseases, infectious diseases or known malignancy

- under treatment with corticosteroids, anti-inflammatory agents or disease modifying
agents

- with known hypersensitivity-allergy to colchicine

- under chronic treatment with colchicine

- with severe renal failure (eGFR < 30 ml/min/1.73 m2)

- with hepatic failure (Child - Pugh class B or C)

- presenting with cardiac arrest

- presenting with ventricular fibrillation

- presenting with cardiogenic shock

- with stent thrombosis

- with angina within 48 hours before infarction

- with previous myocardial infarction

- with occlusion of the left main or left circumflex coronary artery or with evidence of
coronary collaterals to the region at risk on initial coronary angiography (at the
time of admission)

- with metallic implants (ferromagnetic material)